Search PubMed⌕ Search

Biomedical subjects

W Beischer

Publications and source records attributed to W Beischer.

61 records · Page 4Linked to original sources
PubMed1975

Antidiabetic action of somatostatin--assessed by the artificial pancreas.

By means of a glucose-controlled insulin- and glucose-infusion system (GCIGIS) we examined the effect of somatostatin on insulin and glucose requirements following meals or oral glucose loads in juvenile diabetics. In six of seven patients the insulin requirement with somatostatin was remarkably reduced to between 38 per cent and 79 per cent of that of otherwise identical control experiments. No reduction could be found in the seventh case, fed only 575 kcal. In all cases we observed an increase in dextrose demanded from the GCIGIS ranging between 28 per cent and 192 per cent of the control amounts. In addition, a lowering and smoothing of postprandial blood glucose curves caused by somatostatin application was a general finding. It seems to us most likely that the well-known suppression of the secretion of growth hormone and glucagon, both insulin antagonists, is responsible for the antidiabetic action of somatostatin.

Adolescent↗
PubMedDate not supplied

Immunologic properties of biosynthetic human insulin in vitro.

Some immunologic properties of biosynthetic human insulin (BHI) were examined in vitro. An identical behavior was found for BHI and pancreatic human insulin as standard preparation and for A14-mono-labeled BHI and pork insulin as tracer in the insulin radioimmunoassay. BHI proved to be free of human proinsulin and C-peptide. Insulin antibodies in serum of two diabetic patients showed a preferential binding of 125I-bovine insulin. However, the antibody titers were almost identical for A14-mono-labeled BHI and pork insulin. These studies did not reveal any characteristic immunologic properties of BHI compared with highly purified pancreatic human and pork insulin.

Animals↗
PubMedDate not supplied

[Current principles of therapy of diabetes mellitus in old age].

The criteria for the diagnosis of diabetes are the same in all age groups. The main reason for a deterioration of glucose tolerance with age is insulin resistance, primarily concerning glucose uptake of skeletal muscle. The decision of if and how diabetes is treated in old people is a highly individual one depending on the patient's general condition and life circumstances. Acute symptoms are poorly characteristic and can be mistaken as complaints of old age, thus they play the most important role in deciding therapy. Diet is the most important role in deciding therapy. Diet is the most important therapy and the only therapeutic aspect without side-effects. The patients habits must be known before prescribing a practical diet. Besides general principles of a diabetic diet, hyperlipidemia and hypertension, and also deficiencies in nutrients must be taken into account. By reducing insulin resistance, exercise training can excellently support dietary therapy. Additional drug therapy should certainly be started if acute symptoms persist with proper diet, or if fasting glucose concentrations in plasma exceed 200 mg/dl. Acarbose, metformin, sulfonylureas, and insulin are the drugs available, of which mechanisms of action, applications, and side-effects are described. In the order given the efficacy of these drugs as well as the risk of dangerous side-effects increases. If sulfonylureas or insulins are applied for treatment the risks of hypoglycemia must be explained to the patient and his family, and must be prevented by all means. Finally, the importance of treating the diseases accompanying and following diabetes is stressed.

Aged↗